Test Code LAB4900 Adenovirus DNA Detection by PCR, Qualitative
Performing Laboratory
Barnes-Jewish Hospital Molecular Infectious Disease Laboratory
Methodology
Polymerase Chain Reaction (PCR) performed on the DiaSorin Liaison MDX.
Whole blood specimens that are positive by the qualitative adenovirus assay will be automatically sent for quantitative adenovirus whole blood testing.
Infection with adenovirus can manifest in a variety of ways, ranging from fever with upper respiratory symptomatology to diarrhea1. One of the more severe manifestations of adenovirus infection is disseminated disease. This can occur in patients with underlying immunosuppression, particularly suppression in T-cell immunity, and can be fatal. Treatment is available for patients with disseminated adenovirus infection, though has significant side effects2. Close monitoring of adenovirus viral load is essential to balance treatment efficacy and toxicity. Patients with initial qualitative positivity for adenovirus in whole blood specimens require subsequent quantitative testing as soon as possible to prevent treatment delays.
Specimen Requirements
Acceptable Specimens:
Whole blood (Lavender-top/EDTA tube), Bronchoalveolar lavage, Bronchial wash, tracheal aspirate, or Nasopharyngeal Swab in viral transport medium
Collection Procedure:
Blood
1. Draw blood into tube. Avoid hemolysis.
2. Maintain sterility and forward promptly at ambient temperature only.
Bronchial Alveolar Lavage (BAL), Bronchial Washes, or Tracheal Aspirate
1. Aseptically collect at least 1.0 mL of BAL, bronchial wash specimen, or tracheal aspirate.
2. Place specimen in a labeled, screw-capped, sterile container.
3. Maintain sterility and forward promptly.
Note:
1. Specimen source is required
Nasopharyngeal Swab
1. Obtain a vial of universal/viral transport medium (UTM) with collection swab
2. Collect nasopharyngeal specimen
3. Place the swab in labeled UTM vial, break off shaft of swab and discard excess piece of
shaft. To prevent leaking, make sure the swabs do not interfere with tightening cap on vial.
Note:
1. Specimen source is required
Day(s) Test Set Up
Monday-Sunday
Turnaround Time:
STAT: not available
Routine: 1-3 days, Final report available the day of testing
Test Classification and CPT Coding
Test Classification:
This assay utilizes ASR’s (analyte specific reagents) and is not FDA cleared. This test was developed and its performance has been evaluated by the Barnes Jewish Molecular Infectious Disease Laboratory for performance on whole blood, lower respiratory specimens, and NP swabs.
Assay Limit of Detection:
Lower Respiratory Samples: 2,000 copies/mL
Blood: 20,000 copies/mL
NP swabs: 2,000 copies/mL
Limitations:
- The detection of viral nucleic acid is dependent upon proper sample collection, transport, handling and storage. Failure to observe proper procedures in any one of these steps can lead to incorrect results.
- False-negative results may occur if the viruses are present at a level that is below the analytical sensitivity of the assay or if the virus has genomic mutations, insertions, deletions, or rearrangements or if performed very early in the course of illness
CPT Code:
87798, qualitative
87799, quantitative - used only for patients that reflex to quantitative testing. See Methodology section for details.
Reference Values
Negative
Specimen Transport Temperature
Blood-Ambient/Refrigerate /Frozen OK
Bronchial Alveolar Lavage (BAL), Bronchial Washes, or Tracheal Aspirate- Ambient/Refrigerate/Frozen OK
Swabs- Ambient/Refrigerate/Frozen OK
Refrigerated specimens must be tested within 7 days
Frozen specimens must be tested within 30 days
Additional Information
For BJH Laboratory Use Only
Minimum Volume:
Blood (Lavender-top / EDTA tube): 2.0 mL
Bronchial Alveolar Lavage (BAL), Bronchial Washes, or Tracheal Aspirate: 0.5 mL
Laboratory Processing Instructions:
BJH Microbiology will forward to the performing laboratory.
Literature References
1Heim A and Hayden R T. Adenovirus. Manuel of Clinical Microbiology 12th Edition, 2019;106:1831-1846
2Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. doi:10.1182/blood-2016-11-749721